Company: SCLXW
Filing Date: 2025-07-23
Form Type: 424B3
Source: 0001193125-25-163077
Chunk: 235

Company: Scilex Holding Co
Filing Date: 2025-07-23
Form: 424B3
Chunk 235
---
 Option in respect of the Final Subject Warrants for a number of
Warrant Shares equal to the applicable Subject Proceeds divided by Per Share Price (and Purchaser shall issue to Oramed one or more replacement warrants which are the same in all respect as the Subject Warrants other than the date of issuance and a
reduction in the Warrant Shares after giving effect to any such partial exercise of the Option pursuant to this clause (B), which replacement warrants shall thereafter constitute the remaining “” hereunder).

(c) Upon Oramed’s written request at any time following an exercise of its Termination Right pursuant to
, without limitation of the terms and provisions of any Subject Warrant or and , Purchaser shall (and shall cause its Representatives
(as defined in the SPA) and Affiliates to) take all such actions as are necessary to promptly give effect to any exercise by Oramed (or any successors or assigns thereof) of any Subject Warrant, including obtaining any approvals of the board or
stockholders of Purchaser or any of its Affiliates as may be required under applicable Law or the rules of Nasdaq.

(d)
Without limitation of , Purchaser shall hold an annual or special meeting of stockholders (“”) as soon as practicable following the date on which this Agreement has been
terminated pursuant to (the “”) for the purpose of obtaining stockholder approval of the issuance of the Warrant Shares under Nasdaq Listing Rule 5635 (such approval, whether
obtained prior to or following the Termination Date, the “”), with the recommendation of Purchaser’s Board of Directors that such proposals are approved. Purchaser shall (i) promptly prepare and file a
proxy statement with the SEC (the “”) to be sent to Purchaser’s stockholders in connection with the Stockholder Meeting, (ii) call and hold the Stockholder Meeting no later than the date that is 60 days
following the Termination Date, and (iii) use its commercially reasonable efforts to obtain the Stockholder Approval at the Stockholder Meeting. The Proxy Statement shall include the recommendation from the Purchaser’s Board of Directors
that Purchasers’ stockholders vote in favor of the Stockholder Approval. Purchaser shall use its commercially reasonable efforts to solicit from its stockholders proxies in favor of the Stockholder Approval and to obtain the Stockholder
Approval.

8

Purchaser shall respond promptly to any comments received from the SEC with respect to the Proxy Statement, and provide any such comments to Oram